Featured Insight
PRECISIONadvisors Recognized as a Vault Top Ranked Consulting Firm
PRECISIONadvisors has been recognized as a Vault Top Ranked Consulting Firm! This marks PRECISIONadvisors' inaugural appearance on the prestigious Vault Consulting 50 list, which evaluates firms based on confidential employee input covering aspects such as workplace culture and quality of life. The firm secured rankings in four distinct categories: Vault Consulting 50 North America Best Boutique Consulting Firms Best Consulting Firms for Women Best Consulting Firms for Formal Training
PRECISIONadvisors New Office Opening in London
The PRECISIONadvisors team is looking forward to welcoming clients and Precision colleagues to their new office opening this week. The client networking event includes a panel discussion on the evolving marketing access environment in the UK featuring Andrew Walker, David Watson and Neil Grubert. Reach out to Richard Macaulay to attend! * Schedule a meeting with one of our experts * Be sure to attend the two Podium Presentations by Precision's Richard Macaulay on November 14 and 15
Conference: ISPOR Europe 2023
Precision will be at ISPOR Europe, November 12-15, 2023. * Schedule a meeting with one of our experts * Be sure to attend the two Podium Presentations by Precision's Richard Macaulay on November 14 and 15
How High Can Prices Go? Cell and Gene Therapies
Curious how high prices can go in cell and gene therapies? Read our white paper to learn more about developments in the cell and gene therapy payer world.
China’s NRDL 2022 Update: Spotlight on Rare Disease (Part 3 of 3)
With negotiated prices as much as 95% below launch pricing, marketing rare disease therapies in China is a challenge. PRECISIONadvisors Chloe Wang, Katherine Leong, and Cherry Moldovan discuss alternate access channels. Download the free brief (part 3 of 3).
China NRDL 2022 Update – Spotlight on Oncology (Part 2 of 3)
Recent updates to China’s NRDL have a big impact on oncology therapies. PRECISIONadvisors Chloe Wang, Katherine Leong, and Cherry Moldovan explain what that means for multinationals in this free brief (part 2 of 3).
On Demand: NICE Early Scientific Advice: When, Why, and How!
Have you considered using NICE Scientific Advice (SA) to inform your evidence development, trial design, and/or economic modelling? Are you familiar with the concept of NICE SA, but have no direct experience? Or have you used the process before, but want to learn how to optimise your use of it? Join PRECISIONadvisors on July 26 at 9am EST for a complimentary webinar, as we share our experience with NICE SA in a pragmatic discussion of what it can do for you, and best practices for getting the most from NICE SA.
On Demand: Cell and Gene Therapies – How High Can Prices Go?
This ON24 webinar will discuss how cell and gene therapies can be justifiably priced at different levels. We will explore just how high they can extend and also how we can collectively ensure that patients can access these innovations when they are needed. This discussion will be led by David Carr: Senior Director, Global Pricing and Market Access (PRECISIONadvisors), Richard Macaulay: SVP, Global Pricing and Market Access (PRECISIONadvisors).
On Demand Webinar – Paying for Prevention? Payer Access Challenges and Solutions for Preventative Gene Therapies
Launching a therapy has become increasingly challenging, with only 34% of launches meeting their year-one goals (Evaluate Pharma, McKinsey). In addition, launches have also become more complex, with additional stakeholders to consider as well as the careful navigation of siloed, enterprise-wide functions and dynamic, fragmented data solutions. Not surprisingly, the path to a successful launch can be very narrow.
How High Can Prices Go? Cell and Gene Therapies
Curious how high prices can go in cell and gene therapies? Read our white paper to learn more about developments in the cell and gene therapy payer world.
White Paper: “Preventative” Gene Therapies: Perspectives on Payer Access Challenges and Solutions
Gene therapies offer hope for patients with severe genetic diseases by providing long-term benefits and even cures. However, the challenges of evaluating the long-term benefits of these therapies from a payer perspective are considerable. This white paper by PRECISIONadvisors highlights the shift of gene therapy research into more prevalent diseases, and outlines how manufacturers and payers can co—create evidence requirements and models to optimize launch success and sustainability.
New White Paper: Speeding up Patient Access to Innovation: Strategies to Convert Early European Regulatory Approval Into Optimal Reimbursement
Efforts to facilitate patient access to innovative medicines have taken on new urgency in the pandemic era, sharpening drug developers’ focus on the first step in this process: securing regulatory approval.
PRECISIONadvisors Recognized as a Vault Top Ranked Consulting Firm
PRECISIONadvisors has been recognized as a Vault Top Ranked Consulting Firm! This marks PRECISIONadvisors' inaugural appearance on the prestigious Vault Consulting 50 list, which evaluates firms based on confidential employee input covering aspects such as workplace culture and quality of life. The firm secured rankings in four distinct categories: Vault Consulting 50 North America Best Boutique Consulting Firms Best Consulting Firms for Women Best Consulting Firms for Formal Training
PRECISIONadvisors New Office Opening in London
The PRECISIONadvisors team is looking forward to welcoming clients and Precision colleagues to their new office opening this week. The client networking event includes a panel discussion on the evolving marketing access environment in the UK featuring Andrew Walker, David Watson and Neil Grubert. Reach out to Richard Macaulay to attend! * Schedule a meeting with one of our experts * Be sure to attend the two Podium Presentations by Precision's Richard Macaulay on November 14 and 15
Conference: ISPOR Europe 2023
Precision will be at ISPOR Europe, November 12-15, 2023. * Schedule a meeting with one of our experts * Be sure to attend the two Podium Presentations by Precision's Richard Macaulay on November 14 and 15
Access90: Chloe Wang
For pharma companies, NRDL is the primary route of reimbursement in China—and the rules have changed. Find out how, in this 2-minute video with Chloe Wang, PRECISIONadvisors Analyst and a member of the China Centre of Excellence.
Download Now: Precision June Events Calendar
The June Events Calendar is here! Stay up to date with all of the upcoming Precision conferences, on-demand events and recent thought leadership!
Access90: Salvador Alvarez Rio
With the Latin American pharma market expected to grow 10% in the next two years, it pays to gain access. But how? Salvador Alvarez Rio, Senior Engagement Manager at PRECISIONadvisors, explains the power of patient advocacy groups to insist on reimbursement for high-cost advanced medicines.
Access90: William Derrickson
Dystrophic Epidermolysis Bullosa (DEB) is an ultra rare genetic disease with no currently approved treatments. In this Access90, Precision's Will Derrickson discusses the unique market access considerations for Krystal Biotech's anticipated launch of B-VEC, a non-invasive treatment for DEB and the first ever topical gene therapy.
What you need to know about key stakeholders and P&MA dynamics in Latin America for 2023 and beyond
Latin America is a $43 billion pharma market—and regional dynamics matter. PRECISIONadvisor’s dedicated team of experts can help navigate local market access and pricing. Discover what that means for your brand.
Download Now: Precision May Events Calendar
The May Events Calendar is here! Stay up to date with all of the upcoming Precision conferences, on-demand events and recent thought leadership!
Are YOU ready to make the most of China’s evolving pharmaceutical reimbursement landscape?
China, the second largest pharmaceutical market in the world (valued at more than $150 billion), is experiencing a paradigm shift characterized by a booming economy, a growing middle class, and an increasingly aged population with rising disease rates. By reviewing recent changes to the Chinese pricing and market access landscape, PRECISIONadvisors’ Andrea Ong and Laura Montani discuss how manufacturers can capitalize on this booming market.
8 things you need to know NOW about UK market access in 2021…
With the Brexit transition period behind us, the healthcare landscape in the UK is poised for change. Precision's Dimitrios Tzaras & David Carr discuss 8 regulatory, HTA and commercial initiatives likely to shape UK market access in 2021.
Precision Medicine Group Significantly Expands Cell and Gene Therapy Expertise with Acquisition of Project Farma
LEADING BIO-ENGINEERING AND MANUFACTURING SERVICES FIRM CATALYZES THE LAUNCH OF PRECISION’S CELL AND GENE THERAPY OFFERING—'PRECISION ADVANCE’—ADDRESSING THE UNIQUE CHALLENGES OF CELL & GENE THERAPY INNOVATORS, FROM DEVELOPMENT THROUGH COMMERCIALIZATION
Charting A Course Into The Unknown: Manufacturer Considerations In Gene Therapy
The gene therapy market is still in its infancy but poised for significant growth, with an approximate 25% increase in therapies in the pipeline as compared to 2018. However, the launch of a gene therapy is an event with limited case examples to follow and numerous unique considerations.
Market Dynamics to Consider for Gene Therapy Success
What are the most important market dynamics to ensure the success of your gene therapy?
Are You Ready For Dynamic Healthcare Coverage Shifts?
COVID-19 has brought an undeniable impact on the healthcare landscape. Are you prepared for the coming dynamic healthcare coverage shifts?
On-demand Webinar: Stay Ahead of Shifting Coverage Trends — What Is Happening and How to Address It
Historic unemployment rates have dramatically shifted healthcare coverage trends as a result of COVID-19. Watch on-demand with PRECISIONadvisors' Greg Gregory and Eddie Vogel, and learn we can address the impact of these shifts, and help support your teams' ability to answer tough questions moving forward.
On-demand Webinar: Run an Account-Specific Market Access Strategy
Launching a drug requires a robust strategy to understanding payer decision-making. In this webinar with Precision's Brett DiNatale and Diego Etcheto, learn how our rigorous, standardized, 3-step methodology can help you predict future actions for your entire payer spectrum.
On-demand Webinar: Demonstrating the short-term and long-term value of gene and cellular therapies
In this on-demand webinar, a panel of Precision's top gene and cell therapy leaders tackles the challenge of how to demonstrate the short and long-term value of a therapy when clinical data is lacking.
Critical pitfalls to avoid in value-based contracting
Adapted from recent presentations at the AMCP and ISPOR conferences, this webinar will provide an overview of value-based contracting and some of the key challenges to successful implementation.
On-Demand Webinar — HEOR in 2020: 4 Trends for Market Access
This expert panel tackle head-on some of the hottest topics and trends in health economics and outcomes research today, and what you need to know to be successful in 2020.
Download Now: Precision April Events Calendar
The April Events Calendar is here! Stay up to date with all of the upcoming Precision conferences, on-demand events and recent thought leadership!
On Demand: Cell and Gene Therapies – How High Can Prices Go?
This ON24 webinar will discuss how cell and gene therapies can be justifiably priced at different levels. We will explore just how high they can extend and also how we can collectively ensure that patients can access these innovations when they are needed. This discussion will be led by David Carr: Senior Director, Global Pricing and Market Access (PRECISIONadvisors), Richard Macaulay: SVP, Global Pricing and Market Access (PRECISIONadvisors).
Article: The Future of Gene Therapies: Three Trends
Since the first gene therapy procedure more than 30 years ago, the field has seen significant advances and development, but also setbacks and issues. What is the future direction for gene therapies? Precision's Phil Cyr, Richard Macaulay and Andy Kinley identify three future trends and how they might impact safety, manufacturing development, and reimbursement and payment.
What you need to know about key stakeholders and P&MA dynamics in Chile for 2023 and beyond
Latin America is a ripe market for pharma, with large populations and significant unmet needs. Yet the political landscape and fragmented healthcare systems call for expertise. Get the full LatAm brief (all 7 parts) from PRECISIONadvisors’ regional authorities.
What you need to know about key stakeholders and P&MA dynamics in Chile for 2023 and beyond
Across Chile, the public is demanding changes in the healthcare system. What does that mean for pharma? PRECISIONadvisors experts explain in this free brief (part 6 of 7).
Download Now: Precision March Events Calendar
The March Events Calendar is here! Stay up to date with all of the upcoming Precision conferences, on-demand events and recent thought leadership!
